Table 1 Clinical assessment, response to infliximab treatment and HMGB1 expression.
Pat | W | Sex | Age (years) | Disease duration (years) | CRP | Medication | DAS28 | Clinical response | HMGB1 protein | HMGB1mRNA | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MTX | Pred | DAS28 | ACR | ES | CG | ||||||||
1 | 0 | F | 55 | 18 | 107 | 17.5 | 5 * | 6.71 | 1.5 | 1 | |||
9 | 38 | 6.34 | No | 0 | 2 | 1.5 | |||||||
2 | 0 | F | 52 | 6 | 14 | 7.5 | 7.5 | 6.00 | 1.5 | 1.5 | |||
9 | 15 | 4.43 | Mod | 20 | 1 | 0.5 | 0 | ||||||
3 | 0 | F | 58 | 2 | 46 | 10 | 7.91 | 3 | 4 | ||||
9 | 25 | 5.41 | Mod | 50 | 1 | 1.5 | 0 | ||||||
4 | 0 | F | 57 | 4 | 7 | 10 | 4.94 | 2 | 2 | ||||
9 | 34 | 4.41 | No | 20 | 2 | 2 | Up | ||||||
5 | 0 | M | 56 | 7 | 44 | 15 | 5.95 | 2 | 2.5 | ||||
9 | 7 | 2.90 | G | 70 | 3.5 | 3 | |||||||
6 | 0 | F | 69 | 1 | 69 | 15 | 5 | 7.39 | 2 | 3 | |||
9 | 7 | 1.79 | G | 70 | 1.5 | 2.5 | Up | ||||||
7 | 0 | F | 66 | 14 | 34 | 10 | 5.64 | 2 | 2 | ||||
9 | 16 | 4.73 | Mod | 0 | 1 | 0.5 | Down | ||||||
8 | 0 | F | 66 | 10 | 18 | 12.5 | 4.83 | 3.5 | 4 | ||||
9 | 19 | 4.23 | Mod | 0 | 0.5 | 2 | Down | ||||||
9 | 0 | M | 25 | 0.6 | 26 | 17.5 | 7.5 | 5.62 | .5 | 3 | |||
9 | 25 | 3.91 | Mod | 20 | 3 | 4 | |||||||